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Purpose: Gold nanoshells (NSs) have already shown great promise as photothermal actuators 
for cancer therapy. Integrin αvβ3 is a marker that is specifically and preferentially overexpressed 
on multiple tumor types and on angiogenic tumor neovasculature. Active targeting of NSs to 
integrin αvβ3 offers the potential to increase accumulation preferentially in tumors and thereby 
enhance therapy efficacy.
Methods: Enzyme-linked immunosorbent assay (ELISA) and cell binding assay were used to 
study the in vitro binding affinities of the targeted nanoconjugate NS–RGDfK. In vivo biodis-
tribution and tumor specificity were analyzed using 64Cu-radiolabeled untargeted and targeted 
NSs in live nude rats bearing head and neck squamous cell carcinoma (HNSCC) xenografts. The 
potential thermal therapy applications of NS–RGDfK were evaluated by subablative thermal 
therapy of tumor xenografts using untargeted and targeted NSs.
Results: ELISA and cell binding assay confirmed the binding affinity of NS–RGDfK to 
i  ntegrin αvβ3. Positron emission tomography/computed tomography imaging suggested that 
tumor t  argeting is improved by conjugation of NSs to cyclo(RGDfK) and peaks at ∼20 hours 
postinjection. In the subablative thermal therapy study, greater biological effectiveness of targeted 
NSs was implied by the greater degree of tumor necrosis.
Conclusion: The results presented in this paper set the stage for the advancement of integrin 
αvβ3-targeted NSs as therapeutic nanoconstructs for effective cancer therapy.
Keywords: nanoparticle, cyclo(RGDfK), cancer, thermal ablation
Introduction
Gold nanoshells (NSs) are core/shell particles comprising a gold shell and a dielectric 
silica core with peak plasmon resonances tunable to desired wavelengths by   adjusting 
the relative core and shell thicknesses. At near infrared (NIR) wavelengths, light 
penetrates deep within the tissue (up to several centimeters), making this an optimal 
wavelength for biomedical applications. Indeed, NSs that absorb maximally in the 
NIR wavelength and efficiently convert incident light to heat can be readily synthe-
sized (eg, a 120-nm core diameter and a 14-nm-thick shell result in an absorption 
peak between 780 nm and 800 nm). Biodistribution studies indicate that untargeted 
NSs passively accumulate in solid tumors through the enhanced permeability and 
retention (EPR) effect, do not enter healthy tissues to the same extent, and appear to 
be safe and well tolerated.1,2 This tumor-specific accumulation and NIR activation 
have been exploited for thermal ablation of solid tumors using NIR illumination.3,4 
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s  trategies have been pursued by many investigators.5,6 Given 
the r  elatively large size of NSs,7 they are unlikely to penetrate 
deep into tumor parenchyma but are readily sequestered 
within the perivascular space. Therefore, active targeting to 
antigens specific to tumor cells is not expected to achieve 
substantially higher tumor penetration.
In contrast to tumor antigen-targeting strategies, tumor 
vascular targeting has some unique advantages.   Integrins 
are a family of cell adhesion molecules consisting of 
two noncovalently bound transmembrane subunits (α and 
β) that form heterodimers.8 The integrin αvβ3 binds to 
a  rginine–glycine–aspartic acid (RGD)-containing compo-
nents of the   extracellular matrix, blood, and cell surface 
proteins. M  ultiple lines of evidence suggest that this 
integrin   heterodimer can serve as a target for tumor neo-
vascular imaging and image-guided cancer therapies. First, 
integrin αvβ3 is   significantly upregulated on endothelium 
during angiogenesis and on fast-growing solid tumor cells 
but not on quiescent e  ndothelium and normal tissues.9–12 
Second, RGD molecular probes have been developed for 
imaging integrin expression using   different modalities, 
such as magnetic resonance imaging,13 ultrasound,14,15 
optical imaging,16–19 positron emission t  omography 
(PET),20–22 and single-photon emission computed tomog-
raphy (SPECT).22,23 Third, reagents that bind s  electively to 
integrin αvβ3 can be designed by cyclizing peptides with 
selected sequences around the RGD and by synthesizing 
RGD mimics.8 Fourth, in many cancers, higher numbers of 
tumor-associated vessels express integrin αvβ3 than vessels 
in normal t  issue.24 Lastly,   inhibition of i  ntegrin αvβ3 using 
monoclonal a  ntibodies, cyclic RGD   peptide a  ntagonists 
(Figure 1A), and p  eptidomimetics has been shown to 
induce endothelial cell apoptosis, inhibit   angiogenesis, 
and increase endothelial monolayer permeability.25,26 
Collectively, these studies suggest that integrin αvβ3 can 
serve as a selective, but not specific, target for imaging 
and therapy of cancer. Further, cyclic RGD peptides can 
serve as conduits to anchor probes on these integrins, and 
when combined with the EPR effect mediated by leaky 
vasculature and insufficient l  ymphatic drainage of tumors, 
additional accumulations of these conjugated probes may 
enhance this selectivity. In addition to RGD peptides, 
some research groups have synthesized small molecule 
antagonists based on RGD motifs to achieve comparable 
affinity with integrin αvβ3.27–29
In this study we compared the binding affinities to integrin 
αvβ3 of the cyclo(RGDfK) (cyclo(Arg-Gly-Asp-D-Phe-Lys)) 
peptide and the synthesized antagonist 4-[2-(3,4,5,6-tetrahydro-
pyrimidin-2-ylamino)-ethyloxy]benzoyl-2-(S)-[N-(3-amino-
neopenta-1-carbamyl)]-  aminoethylsulfonylamino-h-alanine 
hydrochloride (IAC) (Figure 1B)27 and their NS conjugates 
by three different (ELISAs). The binding specificity of NS-
RGDfK to integrin αvβ3-expressing U87 tumor cells was then 
validated by silver staining assays. In vivo biodistribution 
and tumor specificity were analyzed using 64Cu-radiolabeled 
untargeted NSs and targeted NSs in live rats bearing head and 
neck squamous cell carcinoma (HNSCC) xenografts. Lastly, 
the relative ability of untargeted and targeted NSs to induce 
tissue damage after induction of subablative temperatures 
was assessed in a tumor xenograft model.
Material and methods
Ns synthesis and conjugation
Gold–silica NSs were synthesized as previously described.30 
NS formation was assessed using an ultraviolet-visible (UV-
VIS) spectrophotometer (U-0080D, Hitachi) and Z  etasizer 
(Nano-ZS, Malvern Instruments, Malvern, UK). Integrin 
αvβ3-targeting peptide cyclo-(RGDfK) (molecular weight 
[MW] = 617.71) and control peptide cyclo-(Arg-Ala-Asp-
D-Phe-Lys) (cyclo-(RADfK), MW = 603.68) were pur-
chased from Peptides I  nternational (Louisville, KY, USA). 
Integrin αvβ3 antagonist IAC (MW = 622.14) was provided 
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Figure 1 structures of cyclo (Arg-gly-Asp-D-Phe-Lys) (rgDfK) (A) and the antagonist, 4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethyloxy]benzoyl-2-(s)-[N-(3-amino-
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by Dr Narasimhan Danthi from the Molecular Imaging 
Laboratory at National Institutes of Health. Bifunctional 
ortho-pyridyldisulfide-polyethylene   glycol 2000-N-hydrox-
ysuccinimide ester (OPSS-PEG2k-NHS) was purchased 
from Nektar (Huntsville, AL, USA). Chelating agent S-2-(4-
aminobenzyl)-1,4,7,10-  tetraazacyclododecane tetraacetic acid 
(DOTA) was purchased from Macrocyclics (Dallas, TX, USA). 
The free amine groups of RGDfK, RADfK, IAC, and DOTA 
were conjugated to OPSS–PEG–NHS by mixing 1:1 molar 
ratios overnight at pH 7.4 at room temperature (RT). The 
resulting OPSS–PEG conjugates were then mixed with NS 
solution (in 10 mM phosphate buffer, pH7) at 10,000:1 molar 
ratio overnight at RT on a shaker, allowing the OPSS group to 
conjugate to the gold surface of the particles. The mixture was 
centrifuged, and the supernatant with unconjugated OPSS–
PEG was removed. The pellets of NS–peptide, NS–IAC, or 
NS–DOTA were resuspended in phosphate buffer and analyzed 
by a spectrophotometer and Zetasizer to determine the NS 
concentration and size, respectively, for further conjugation. 
To prepare NS with both RGDfK and DOTA on the surface, 
OPSS–PEG–RGDfK and OPSS–PEG–DOTA were mixed 
with NS at a 5000:1 molar ratio followed by the incubation 
and separation steps.
In vitro binding affinity assays
competitive eLIsA for rgDfK and IAc
Purified integrin αvβ3 protein (Chemicon International, 
Temecula, CA, USA) was coated on 96-well plates at 
0.1 µg/well. After overnight incubation at 4°C, the plates 
were washed (washing buffer: 1X phosphate buffered saline 
[PBS] with 0.05% Tween 20) and then blocked with b  locking 
buffer (1X PBS with 2% bovine serum albumin [BSA]) at 
RT for 2 hours. The blocking buffer was removed, and the 
plates were inoculated in triplicate with both RGDfK and 
IAC at a typical starting concentration of 0.125 µg/mL. Serial 
dilutions were prepared in the 96-well plates with blocking 
buffer supplemented with 0.9 mM of Ca2+ and 0.5 mM of 
Mg2+. After 30 minutes of incubation, 0.2 µg of biotinylated 
vitronectin solution (Molecular Innovations, MI, USA) was 
added to each well as a standard competitor. The plates were 
incubated at RT for 3 hours then washed, and the bound 
vitronectin was detected using 0.01 µg/well of avidin–horse 
radish peroxidase (HRP) conjugate (Pierce, Rockford, IL, 
USA). After washing, 100 µL of substrate s  olution was 
added to each well and then the luminescence was read 
(Figure 2A). The resulting luminescence signal intensity 
was plotted against RGDfK and IAC concentration and fit-
ted by SigmaPlot 10.0 (SYSTAT Software, Inc., San Jose, 
CA, USA), and the concentrations of inhibitor p  roducing 
50% inhibition (IC50) of vitronectin binding to integrin αvβ3 
were calculated based on the curve fittings.
sandwich eLIsA for Ns–rgDfK and Ns–IAc
Purified integrin αvβ3 protein was coated on 96-well plates as 
described previously. The plates were inoculated in t  riplicate 
with NS–PEG5K (control), NS–RGDfK, and NS–IAC, with 
a typical starting NS concentration of 1 optical density (OD). 
1 OD NS is approximately 3∼4 pM. Serial dilutions were pre-
pared in the 96-well plates using blocking buffer c  ontaining 
Ca2+ and Mg2+ and then incubated at RT for 1 hour. The 
detection antibody biotin-anti-PEG (Epitomics, Burlingame, 
CA, USA), which recognizes the methoxy group of the 
PEG5K, was added to each well at 0.05 µg/well. The plates 
were incubated at RT for 1 hour then washed, and the bound 
biotin–anti–PEG was detected using avidin–HRP c  onjugate 
at 0.005 µg/well. After washing, 100 µL of substrate solution 
was added to each well and then the luminescence was read 
(Figure 2B). The resulting luminescence signal intensity was 
plotted against NS concentration and fitted by SigmaPlot 
10.0. The half-maximal binding values (Kd) were calculated 
based on the curve fittings.
competitive eLIsA for Ns–rgDfK and Ns–IAc
Purified integrin αvβ3 protein was coated on 96-well plates as 
described previously. The plates were inoculated in triplicate 
with RADfK (control), RGDfK, and IAC with a typical starting 
concentration of 50 µM (100 µL/well). Serial dilutions were 
prepared in the 96-well plates using blocking buffer containing 
Ca2+ and Mg2+ and then incubated at RT for 0.5 hour, followed 
by addition of NS–RGDfK (0.5 OD, 100 µL/well) as competi-
tor, and incubation for 2.5 hours. After extensive washing, the 
detection antibody biotin–anti-PEG (0.05 µg/well) was added 
to each well. The plates were incubated at RT for 1 hour then 
washed, and the bound biotin–anti-PEG was detected using 
avidin–HRP conjugate at 0.005 µg/well with 1-hour incuba-
tion. After washing, 100 µL of substrate solution was added 
to each well and then the luminescence was read (Figure 2C). 
The resulting luminescence signal intensity was plotted against 
NS c  oncentration and fitted by SigmaPlot 10.0, and the IC50 
values were calculated based on the curve fittings.
cell adhesion assay
U87 human glioblastoma cell lines (ATCC, Manassas, VA, 
USA) were cultured under standard conditions and grown 
to 80% confluence in 48-well plates. Cells were rinsed 
three times in PBS (pH 7.4). NS–RGDfK and NS–PEG5K International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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were mixed in the cell growth medium to obtain samples with 
1.25 OD, which were then added to the U87-coated plate with 
300 µL/well and incubated for 45 minutes at 37°C. Cells in 
PBS served as negative control. Cells were rinsed three times 
in PBS and fixed with 2% glutaraldehyde for 15 minutes and 
then rinsed three times with deionized water. A silver staining 
kit (Amersham Biosciences, Piscataway, NJ, USA) was used 
to stain cells, depositing silver on the NSs surfaces, to allow 
visualization of NS binding to cells via light microscopy 
with 40× magnification.
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Figure 2 schematic drawings (left) and results (right) of the three eLIsAs. (a) competitive eLIsA of vitronectin against rgDfK and the antagonist IAc on an integrin αvβ3 coated 
plate. The absorbance of hrP-avidin is proportional to the amount of the biotinylated vitronectin on the plate. (b) sandwich eLIsA of Ns-Peg5K (control), Ns-rgDfK and Ns-
IAc on an integrin αvβ3 coated plates. The absorbance of hrP-avidin is proportional to the amount of the blocker Peg5K on Ns and therefore, to the number of Ns binding to 
the integrin αvβ3. (c) competitive eLIsA of Ns-rgDfK against rgDfK and IAc on an integrin αvβ3 coated plates. The absorbance of hrP-avidin is proportional to the amount 
of the blocker Peg5K on Ns and therefore, to the number of Ns binding to the integrin αvβ3. All values are means of duplicate assays in the three eLIsA experiments. 
Abbreviations: eLIsA, enzyme-linked immunosorbent assay; hrP, horse radish peroxidase; IAc, 4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethyloxy]benzoyl-2-(s)-
[N-(3-amino-neopenta-1-carbamyl)]-aminoethylsulfonylamino-h-alanine hydrochloride; Ns, nanoshell; Peg, polyethylene glycol; rADfK, Arg-Ala-Asp-D-Phe-Lys; rgDfK, 
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radiolabeling and imaging
radiolabeling procedure
All the radioisotope work was performed at the   Department 
of Radiology, University of Texas Health S  cience Center 
(UTHSC)-San Antonio, TX, USA.  64CuCl2 (Washington 
University, St Louis, MO, USA) was diluted in 30 mM 
ammonia citrate buffer (pH 6.5). Then, ∼1000 µCi of 64Cu 
was added to 200 µL of the solutions of NS–DOTA and NS 
with both RGDfK and DOTA (concentrations of NSs were 
about 1 nM) and incubated at 37°C for 90 minutes. Then 
the blocking agent PEG5K-SH (Nektar) was added to NS 
solution at 300,000:1 molar ratio and incubated at RT on a 
shaker for 1 hour. The mixtures were then centrifuged to 
remove unconjugated 64Cu and PEG5K. The 64Cu activity of 
the supernatant and pellet was measured in a dose calibrator 
(Atomlab 100, Biodex, Shirley, NY, USA). Labeling efficien-
cies were calculated by using the equation [activity in pellet/
(activity in supernatant + activity in pellet)] × 100.
Animal model and in vivo PeT imaging
An HNSCC xenograft model in nude rats was established via 
subcutaneous inoculation of the HNSCC cell line SCC-4.31 
Animal experiments with radioactive agents were carried out 
at UTHSC according to the NIH Animal Use Guidelines. On 
the day of imaging, the average tumor volume of the nude rats 
was 1.2 cm3. During all procedures, the nude rats (∼150 g) 
were anesthetized with intraperitoneal Avertin® (400 mg/kg) 
by intraperitoneal injection. 64Cu-NS (∼800 µCi of 64Cu) and 
64Cu-NS–RGDfK (∼600 µCi of 64Cu) were injected   manually 
into the rats’ tail veins at about 0.5 mL per minute. PET 
imaging was performed at 1 hour, 4 hours, 20 hours, and 
44 hours postinjection of radiolabeled NS with the FLEX 
X-PET/CT/SPECT scanner (Gamma Medica-Ideas, Inc., 
Northridge, CA, USA) followed by CT image acquisition 
(80 kVp, 0.25 mA, 256 projections).
In vivo analysis of thermoablation efficacy
In a subcutaneous colorectal cancer xenograft model using 
HCT116 human tumor cells in nude mice, 100 µL (∼0.4 nM) 
of NS–PEG5K and NS–RGDfK solutions were injected via 
the tail vein of the animals (two mice in each group). After 
24 hours, thermocouple probes were inserted into the center 
and the base of the tumor at about 5 mm depth from the 
s  urface. T-type (copper-constantan) needle thermocouple 
probes (HYP1-30-1/2-T-G-60-SMP-M, Omega E  ngineering) 
were used. The probe alone did not generate heat as tested by 
irradiating the probe with the laser. The NIR laser power was 
set at values predicted to result in s  ubablative t  emperatures 
based on an Arrhenius model32 of thermal injury (47°C for 
10 minutes was predicted to achieve 50% cell kill with untar-
geted NSs, a level that would allow comparison with agents 
that potentially increased the efficacy of   thermoablation). 
With a 1.2 W 75% duty cycle, 808 nm NIR laser and a spot 
size of 1 cm, consistent temperature elevation to 47°C was 
achieved within 5 minutes at the center of the tumor and 
was maintained steadily for 10 minutes in the untargeted NS 
group. Tumors were excised 2 hours after thermal therapy 
following pretreatment with NS–PEG5K and conjugated 
NS–RGDfK and stained with hematoxylin and eosin.   Tissues 
were observed by Olympus DP 70 camera fitted on a Nikon 
Microphot-FXA microscope, and images captured using 
Olympus DP software.
Results and discussion
NSs used in this study were manufactured to comprise a 
silica core (∼120 nm in diameter) and a gold shell (8∼10 nm) 
to absorb light at NIR wavelengths. The UV–VIS spectrum 
confirmed the NS absorbance peak at ∼760 nm. Zetasizer 
measurements confirmed the NS diameter of 140 nm and 
zeta potential of -50 mV . By adapting a method that has 
been developed for conjugation of molecules with amine 
groups,2,4 NSs were conjugated to cyclic RGD peptides, 
IAC, or DOTA through bifunctional PEG. Dynamic light-
scattering measurements showed that after surface modifica-
tion the NS size increased to ∼170 nm in diameter, and zeta 
potential changed to around -5 mV .
The binding affinities and specificities of RGDfK and 
IAC for integrin αvβ3 receptor were measured by a competi-
tive ELISA. Serial dilutions of these peptides were assayed 
for their ability to compete with biotinylated   vitronectin for 
the immobilized integrin αvβ3 receptor. After obtaining the 
curve fittings by SigmaPlot (Figure 2A), the calculated IC50 
  concentration of inhibitors RGDfK and IAC for vitronec-
tin binding to integrin αvβ3 were 4.05 nM and 3.38 nM, 
  respectively. These results confirmed the   relatively compara-
ble binding affinities of IAC and RGDfK to   integrin αvβ3 pro-
tein and closely matched the reported IC50 of 2.94 ± 0.19 nM 
for IAC by Burnett et al.27 The lower IC50 of RGDfK than that 
noted by Burnett et al for   cyclo-(RGDfV) (6.41 ± 0.49 nM) 
might be due to the different amino acids in the two peptides 
valine (V) and lysine (K), with the amine group in lysine 
potentially affording greater protein binding.
Subsequently, a sandwich ELISA was used to compare the 
binding affinities of NS–RGDfK, NS–IAC, and N  S–PEG5K 
(control, no targeting molecule). Serial dilutions of these agents 
were added to an integrin αvβ3-coated plate prior to washing International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and detection of bound NSs. As NSs are not readily detected 
on ELISA plates, the PEG coating was used as a surrogate 
for their presence. This sandwich ELISA therefore employed 
a biotinylated anti-PEG antibody that recognizes the methoxy 
group of the PEG5K. The antibody was subsequently detected 
by HRP–avidin. Figure 2B shows that control NS–PEG5K had 
no detectable binding to the integrin αvβ3, whereas   NS–RGDfK 
and NS–IAC had increasing binding to the integrin αvβ3 with 
increasing concentration. The Kd values for NS–RGDfK and 
NS–IAC were 0.267 OD and 0.288 OD, respectively, calculated 
based on the SigmaPlot curve fitting.
In the third competitive ELISA, serial dilutions of the 
competitors RGDfK, IAC, and RADfK (negative control) 
were pre-incubated in separate wells of an integrin αvβ3-
coated plate. The targeted NS–RGDfK (concentrated to give 
0.5 OD at 800 nm) particles were then added to all the wells 
to compete with RGDfK or IAC for binding. Biotin-labeled 
anti-PEG antibody and HRP–avidin was used for detection 
as before. Figure 2C shows that negative control RADfK 
did not have any detectable competition with NS–RGDfK, 
whereas RGDfK and IAC did compete with NS–RGDfK for 
binding to the integrin. The IC50s of RGDfK and IAC were 
0.267 and 0.197 µM, respectively. Because of the relatively 
small difference in binding affinity between RGDfK and IAC 
for all three ELISAs, further in vitro and in vivo experiments 
were performed with NS–RGDfK.
The in vitro binding affinity and specificity of NS–RGDfK 
was tested using U87 glioblastoma cells that express abundant 
integrin αvβ3. Cells were incubated with PBS, NS–PEG5K, 
and NS–RGDfK and treated with a silver staining kit.   Figure 3 
shows that the two controls (PBS and NS–PEG5K) had no 
detectable binding to cells, and NS–RGDfK bound s  pecifically 
and avidly to integrin αvβ3-overexpressing cells. For all the 
in vitro affinity studies, we found that a small amount of Ca2+ 
(0.9 mM) and Mg2+ (0.5 mM) must be added to the b  uffer or 
cell growth medium for RGDfK to bind to the integrin αvβ3. 
Hu et al have reported how Ca2 and Mg2+ regulate ligand bind-
ing to β3 integrins.33 They concluded that low concentrations of 
Ca2+ (µM) promoted the binding of the ligand, whereas higher 
concentrations of Ca2+ (mM) blocked the binding. This study 
revealed that there are two classes of cation binding sites on the 
β3-containing integrins. The first class of sites promotes ligand 
binding to integrin when occupied by divalent cations, and the 
second class of sites is allosteric to the ligand binding site and 
highly specific for Ca2+ and when occupied increases the dis-
sociation rate between RGD and integrin.34
After confirming biochemical and in vitro binding affini-
ties of NS–RGDfK, we evaluated its stability,   biodistribution, 
and efficacy in imaging integrin αvβ3 in a solid tumor model 
in vivo by dual labeling NSs with a radionuclide (64Cu) and the 
RGDfK peptide. We have used both 64Cu and 111In for radio-
labeling of gold NSs.35,36 The PET and SPECT images of the 
rats showed that both 64Cu and 111In appeared to be useful for 
tracking the in vivo distribution of NSs. The b  iodistribution 
data determined with 111In were very close to those of 64Cu, 
but image quality was better with the 64Cu. This is likely due 
to the more efficient detection of the 64Cu with the PET ring 
coincidence imaging system than with the SPECT rotating 
AB
C
Figure 3 silver staining of integrin αvβ3 overexpressing U87 glioma cancer cells with PBs (A), Ns–Peg5K (B), and Ns–rgDfK (C) solutions. Images were taken by light 
microscope with 40× magnification. 
Abbreviations: Ns, nanoshell; PBs, phosphate buffered saline; Peg, polyethylene glycol; rgDfK, Arg-gly-Asp-D-Phe-Lys.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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camera system. Therefore, PET imaging with 64Cu was used 
for the NS imaging studies described in this paper.
The 64Cu radiolabeling efficiencies were 81.3% and 84.2% 
for NS and NS–RGDfK, respectively. Using PET/CT imaging, 
we monitored the in vivo distribution of radiolabeled NS-
PEG and NS–RGDfK at various time points after intravenous 
injection through the tail vein into nude rats with HNSCC 
  xenografts. Figure 4 shows PET/CT fusion images (top) 
and PET sagittal images (bottom) of rats at 1 hour, 4 hours, 
20 hours, and 44 hours postinjection. Our previous studies sug-
gested that the radioisotope was not cleaved from the NSs, so 
we believe that our images and biodistribution data truly reflect 
the location of NSs.2 Neither NS–PEG nor NS–RGDfK showed 
obvious a  ccumulation within tumors at 1 hour postinjection. 
H  owever, NS–RGDfKs   progressively a  ccumulated in the 
tumor, beginning at 4 hours postinjection and r  eaching an 
  apparent   maximum accumulation at   approximatly 20 hours 
postinjection, f  ollowed by gradual decline in tumor-specific 
a  ccumulation by 44 hours postinjection, whereas untargeted 
NS accumulation in tumors was less pronounced during each of 
these time points. These results suggest that RGDfK conjuga-
tion improves NS a  ccumulation within tumors and that laser 
treatment for photothermal applications should optimally occur 
at ∼20–44 hours postinjection. The animals were s  acrificed at 
46 hours postinjection, and major organs were collected for 
analysis of specific tissue a  ccumulations. The amount of NSs 
NS–RGDfK
NS–PEG
1 hour 4 hours2 0 hours 44 hours
Figure 4 PeT/cT fusion and PeT sagittal images of two nude rats bearing hNscc xenograft at 1 hour, 4 hours, 20 hours, and 44 hours post tail-vein injection of 64cu-Ns 
and 64cu-Ns–rgDfK. The arrows are pointing at the tumor. 
Abbreviations: cT, computed tomography; hNscc, head and neck squamous cell carcinoma; Ns, nanoshell; Peg, polyethylene glycol; PeT, positron emission tomography; 
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in the tissue samples as estimated by gamma well c  ounter 
was expressed as a p  ercentage of injected dose per organ 
(see Supplementary Table 1). The gold content per gram 
of tissue was also estimated by neutron activation analysis 
(NAA) (see Supplementary Figure 1). These results confirm 
the expected accumulation of NSs within the liver and spleen 
and clearance from the tumor in both targeted and untargeted 
NS-treated animals at a late time point.
In addition to potential imaging applications of N  S–
RGDfK, the feasibility of using these targeted probes 
for improved in vivo photothermal efficiency was also 
  investigated. Assuming the targeted NSs were more biologi-
cally effective as thermal therapy conduits, we expected to 
observe more necrosis in tumors laden with these particles 
than the untargeted particles if a subablative thermal treat-
ment was delivered. First, an in vivo model for subablative 
thermal treatment was created. This was based on an Arrhe-
nius m  athematical prediction model32 of thermal injury, 
which predicted that a sustained stable temperature of 47°C 
for 10 m  inutes would result in ∼50% cell death. Next, in a 
cohort of nude mice harboring ∼1 cm subcutaneous HCT116 
  colorectal cancers on their right thighs, laser settings that would 
result in these temperatures were established. The NSs were 
injected intravenously and subablative thermal t  reatments 
were c  onducted 24 hours after the injection. Finally, the effect 
of such treatment was compared between two mice injected 
with similar particle concentrations (∼40 fmol) of untargeted 
and targeted NSs. The targeted NSs treatment group had more 
profound hemorrhage during treatment than the untargeted 
NSs treatment group. Greater amounts of hemorrhagic and 
necrotic debris were evident within the tumor core upon 
sectioning of the tumors from the targeted treatment group 
than the untargeted treatment group. As noted in Figure 5, 
the lower magnification images (A and C, 4×) demonstrate 
greater necrosis in the vascular-targeted group, suggestive 
of more significant vascular disruption. The results suggest 
that greater tumor and tumor vascular s  pecificity via the 
active targeting technique improves the efficacy of thermal 
therapy. The observed enhancement in therapeutic efficacy 
is attributed to the higher tumor concentrations of targeted 
NSs as well as the possibly more intense focal temperature 
hot spots generated in the vicinity of v  ascular-targeted NSs, 
resulting in more vascular disruption.
Conclusion
In this work we investigated the binding affinity of cyclo-
(RGDfK) peptide and the antagonist IAC, as well as their 
NS conjugates to the integrin αvβ3 by ELISA. We found that 
IAC has similar affinity to integrin αvβ3 as RGDfK in the 
competitive ELISA and the sandwich ELISA and that the 
difference is not as significant as previous reports.27 Because 
of the relatively small difference in the binding affinity to 
AB
D C
AB
D C
AB
D C
Figure 5 hematoxylin and eosin stain of tumors excised immediately following sub-ablative thermal therapy using untargeted (A and B) Nss and vascular-targeted (C and D) 
NSs. Images on the left are lower magnification images (A and C, 4×), whereas images on the right are higher magnification images (B and D, 10×). Arrows represent the 
width of areas of necrosis observed. 
Abbreviation: Nss, gold nanoshells.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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integrin αvβ3 between NS–RGDfK and NS–IAC, we pursued 
further experiments with NS–RGDfK. We confirmed potent, 
selective, and specific NS–RGDfK adhesion to integrin 
αvβ3-expressing U87 tumor cells by silver staining. We also 
documented in vivo tumor-specific accumulation of conju-
gated NSs and nonspecific accumulation of probe within the 
liver and spleen at four different time points. Biodistribution 
analysis of untargeted and targeted NSs by measurement of 
residual radioactivity and NAA confirmed that both targeted 
and untargeted NSs are cleared from the circulation by the 
liver and spleen and suggested that integrin αvβ3 targeting 
using RGDfK improved NS accumulation in tumors. Lastly, 
we confirmed increased biological efficacy of conjugated 
NSs for potential thermoablation applications.
As demonstrated in multiple cancers, integrin αvβ3 is a 
crucial cell adhesion and signaling molecule that promotes the 
proliferation, survival, drug-resistant properties, and   metastatic 
potential of cancer cells. This specific and p  referential overex-
pression noted across multiple tumor types makes targeting of 
integrin αvβ3 for imaging and therapy p  articularly a  ppealing, 
as it offers a class solution to the challenge posed by het-
erogeneity of tumor-specific antigens across diverse tumor 
types. Furthermore, integrin αvβ3 l  ocalization to angiogenic 
neovascular endothelia offers greater t  argeting potential for 
larger biomolecules and nanoparticles that are less capable 
of penetrating deep into tumor parenchyma across interstitial 
spaces. We demonstrate here that integrin αvβ3-targeted NSs 
serve as potent theranostic agents that facilitate enhanced imag-
ing and treatment of tumors.
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Table S1 Biodistribution data of 64cu-Ns and 64cu-Ns–rgDfK in 
hNscc xenograft-bearing nude rats at 46 hours postinjection.
Organ 64Cu-NS 64Cu-NS-RGDfK
Tumor 0.97 1.20
spleen 4.93 8.77
Liver 16.39 13.01
Lung 0.31 0.34
Kidney 1.76 1.58
Blood 2.26 1.98
skin 4.80 5.04
Muscle 6.80 7.47
Bone 6.02 8.97
heart 0.17 0.20
stomach 0.76 1.22
Intestine 5.21 7.83
cecum 3.16 4.62
Bladder 0.02 0.11
Testis 0.62 0.61
Brain 0.06 0.06
Note: Data are presented as percentage injected dose per organ (% ID/organ).
Supplementary data
Biodistribution studies
All the animals were used in the imaging studies were 
anesthetized and then sacrificed at 46 hours postinjection. 
The organs of interest were removed and wet weighed. The 
radioactivity in the tissues was measured using a γ-counter 
(Wallac 1480, Perkin Elmer Life Sciences, Boston, MA, 
USA). The radioactivity of the tissue samples was calibrated 
against a known aliquot of the injectate. The percentage 
injected dose per organ (%ID/organ) values were calculated 
using the following equation:
%
() () ID
Organ
cpm in sample background correction factor
=
-× ×100 0
(cpm in standard)
injection volume
(standard volume)
×
()
Major organs that showed high concentrations of other 
types of nanoparticles in previous biodistribution studies1–4 
were also subjected to neutron activation analysis (NAA). 
Portions of tumor, spleen, liver, lung, and kidney tissue 
were collected, wet weighed, and allowed to decay for 
2 weeks. The samples were placed into precleaned and labeled 
  polyethylene irradiation vials. After the wet sample weight 
was calculated and recorded, the samples were covered and 
dried under a heat lamp for 48 hours before delivery into 
the high temperature nuclear reactor core for NAA gold 
  measurements. The procedure of NAA for trace gold quan-
tification in animal tissues has been described elsewhere.5 
The data were reported as gold mass versus the original wet 
sample mass.
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Figure  S1  Neutron  activation  analysis  for  concentration  of  gold  in  tumor, 
spleen, liver, lung, and kidney at 46 hours postinjection of Ns–Peg (control) and 
Ns–rgDfK.